A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota

Molecular Nutrition and Food Research

Volumn 61, Issue 8, 2017, Pages

  Rivero Gutiérrez, Belén ^a   Gámez Belmonte, Reyes ^a   Suárez, María Dolores ^a   Lavín, José Luis ^b   Aransay, Ana María ^b   Olivares, Mónica ^c   Martínez Augustin, Olga ^a   Sánchez de Medina, Fermín ^a   Zarzuelo, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b CIC BIOGUNE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Barrier function; Fructose; Leptin; Metabolic syndrome; Microbiota

Indexed keywords

ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1, RAT; FABP1 PROTEIN, RAT; FATTY ACID BINDING PROTEIN; FRUCTOSE; FRUCTOSE OLIGOSACCHARIDE; OLIGOSACCHARIDE; SYNBIOTIC AGENT; VOLATILE FATTY ACID;

ANIMAL; DIET; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; INSULIN RESISTANCE; INTESTINE FLORA; LACTOBACILLUS FERMENTUM; MALE; METABOLIC SYNDROME X; METABOLISM; NONALCOHOLIC FATTY LIVER; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, VOLATILE; FRUCTOSE; GASTROINTESTINAL MICROBIOME; INSULIN RESISTANCE; LACTOBACILLUS FERMENTUM; MALE; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGOSACCHARIDES; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADIPONECTIN; SYNBIOTICS;

EID: 85020269139     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201600622     Document Type: Article

References (34)

1. Popkin, B. M., Adair, L. S., Ng, S. W., Global nutrition transition and the pandemic of obesity in developing countries. Nutr. Rev. 2012, 70, 3–21.
2. Brandsma, E., Houben, T., Fu, J., Shiri-Sverdlov, R. et al., The immunity-diet-microbiota axis in the development of metabolic syndrome. Curr. Opin. Lipidol. 2015, 26, 73–81.
3. Sánchez de Medina, F., Romero-Calvo, I., Mascaraque, C., Martínez-Augustin, O., Intestinal inflammation and mucosal barrier function. Inflamm. Bowel Dis. 2014, 20, 2394–2404.
4. Sanchez de Medina, F., Ortega-Gonzalez, M., Gonzalez-Perez, R., Capitan-Canadas, F. et al., Host-microbe interactions: the difficult yet peaceful coexistence of the microbiota and the intestinal mucosa. Br. J. Nutr. 2013, 109(Suppl 2), S12–20.
5. Blaut, M., Gut microbiota and energy balance: role in obesity. Proc. Nutr. Soc. 2015, 74, 227–234.
6. Cani, P. D., Van Hul, M., Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr. Opin. Biotechnol. 2015, 32, 21–27.
7. Rastall, R. A., Gibson, G. R., Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. Curr. Opin. Biotechnol. 2015, 32, 42–46.
8. Beserra, B. T., Fernandes, R., do Rosario, V. A., Mocellin, M. C. et al., A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin. Nutr. 2015, 34, 845–858.
9. Peran, L., Camuesco, D., Comalada, M., Nieto, A. et al., Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int. J. Colorectal Dis. 2006, 21, 737–746.
10. Mane, J., Loren, V., Pedrosa, E., Ojanguren, I. et al., Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm. Bowel Dis. 2009, 15, 1155–1163.
11. Tomaro-Duchesneau, C., Saha, S., Malhotra, M., Jones, M. L. et al., Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl. Microbiol. Biotechnol. 2014, 98, 115–126.
12. Merino-Aguilar, H., Arrieta-Baez, D., Jimenez-Estrada, M., Magos-Guerrero, G. et al., Effect of fructooligosaccharides fraction from Psacalium decompositum on inflammation and dyslipidemia in rats with fructose-induced obesity. Nutrients 2014, 6, 591–604.
13. Banuelos, O., Fernandez, L., Corral, J. M., Valdivieso-Ugarte, M. et al., Metabolism of prebiotic products containing beta(2-1) fructan mixtures by two Lactobacillus strains. Anaerobe 2008, 14, 184–189.
14. Bligh, E. G., Dyer, W. J., A rapid method of total lipid extraction and purification. Canadian J. Biochem. Physiol. 1959, 37, 911–917.
15. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P. et al., Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 9066–9071.
16. de Castro, G. S., Deminice, R., Simoes-Ambrosio, L. M., Calder, P. C. et al., Dietary docosahexaenoic acid and eicosapentaenoic acid influence liver triacylglycerol and insulin resistance in rats fed a high-fructose diet. Marine Drugs 2015, 13, 1864–1881.
17. Payne, A. N., Chassard, C., Lacroix, C., Gut microbial adaptation to dietary consumption of fructose, artificial sweeteners and sugar alcohols: implications for host-microbe interactions contributing to obesity. Obesity Rev. 2012, 13, 799–809.
18. Crouzoulon, G., [Kinetic properties of the fructose influx across the brush border of the rat jejunum. Effects of a diet rich in fructose]. Arch. Int. Physiol. Biochim. 1978, 86, 725–740.
19. Macfarlane, S., Macfarlane, G. T., Regulation of short-chain fatty acid production. Proc. Nutr. Soc. 2003, 62, 67–72.
20. Zhu, L., Baker, S. S., Gill, C., Liu, W. et al., Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57, 601–609.
21. van Best, N., Jansen, P. L., Rensen, S. S., The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol. Internat. 2015, 9, 406–415.
22. Albarracin, M., Weisstaub, A. R., Zuleta, A., Mandalunis, P. et al., Effects of extruded whole maize, polydextrose and cellulose as sources of fibre on calcium bioavailability and metabolic parameters of growing Wistar rats. Food Funct. 2014, 5, 804–810.
23. Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M. et al., Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140, 976–986.
24. Schwiertz, A., Taras, D., Schafer, K., Beijer, S. et al., Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010, 18, 190–195.
25. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V. et al., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027–1031.
26. Ritze, Y., Bardos, G., Claus, A., Ehrmann, V. et al., Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014, 9, e80169.
27. Miele, L., Valenza, V., La Torre, G., Montalto, M. et al., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009, 49, 1877–1887.
28. Wieland, A., Frank, D. N., Harnke, B., Bambha, K., Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2015, 42, 1051–1063.
29. Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P. D. et al., Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab 2015, 22, 658–668.
30. Spruss, A., Kanuri, G., Wagnerberger, S., Haub, S. et al., Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009, 50, 1094–1104.
31. Minter, R. M., Bi, X., Ben-Josef, G., Wang, T. et al., LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction. Am. J. Physiol. Gastrointest. Liver. Physiol. 2009, 296, G45–G54.
32. Liu, J., Zhuang, Z. J., Bian, D. X., Ma, X. J. et al., Toll-like receptor-4 signaling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. Clin. Exper. Pharmacol. Physiol. 2014, 41, 482–488.
33. Kolaczynski, J. W., Nyce, M. R., Considine, R. V., Boden, G. et al., Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes. 1996, 45, 699–701.
34. Hwang, I., Park, Y. J., Kim, Y. R., Kim, Y. N. et al., Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J. 2015, 29, 2397–2411.